Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (40)
  • Allergen immunotherapy (76)
  • AllergoOncology (12)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (194)
  • Allied health and primary care (17)
  • Anaphylaxis (99)
  • Artificial Intelligence (10)
  • Asthma (122)
  • Basic immunology (54)
  • Biologicals (70)
  • Biomarkers (51)
  • Comparative veterinary allergology (1)
  • COVID19 (7)
  • Dermatology (103)
  • Drug allergy (145)
  • ENT (20)
  • Environmental allergy and climate change (29)
  • Eosinophilic esophagitis (20)
  • Epidemiology (60)
  • Epithelial cell biology (8)
  • Food allergy (175)
  • Genomics and proteomics (16)
  • Immune deficiencies and autoimmunity (70)
  • Immunomodulation and nutrition (12)
  • Infections (19)
  • Insect venom hypersensitivities (15)
  • Mastocytosis and mast cells (22)
  • Microbiome (7)
  • Occupational allergy (22)
  • Ocular allergy (5)
  • One Health (12)
  • Pediatrics (118)
  • Prevention (36)
  • Systems medicine (13)
Poster available until
  • Until platform closure (46)
Poster categories
  • e-Thematic Poster Session (93)
  • x Thematic Poster Session (980)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (5)
  • L-TPS17 (13)
  • L-TPS18 (9)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • TPS48 (5)
  • TPS49 (5)
  • TPS51 (1)
  • TPS52 (12)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (1)
  • TPS57 (11)
  • TPS58 (1)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (1)
  • TPS62 (8)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (7)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
980 results
Thumbnail

D2.343 - Use of IDDA 2.1 score in Common Variable Immunodeficiency (CVID): a single center experience

Thumbnail

D2.344 - Unraveling the Mysteries of Chronic Granulomatous Disease: A Case of detected Protein Deficiency Amidst Negative Genetic Screening

Thumbnail

D2.345 - Conformations of HVEM engaged in its Trans and Cis interactions are caused by two kinds of post-translational folding

Thumbnail

D2.346 - Assessment of the safety of allogenic natural killer cells in the treatment of metastatic colon cancer

Thumbnail

D2.347 - Allergen-Specific T Cells to House Dust Mite are absent on the circulation of local allergic rhinitis patients

Thumbnail

D2.348 - Clinical Course of Hereditary Angioedema Patients Transitioning off Androgens

Thumbnail

D2.349 - Hereditary Angioedema in Bulgaria: an update on patient characteristics and treatment modalities

Thumbnail

D2.35 - Prevalence of the sensitivity to aeroallergens among patients with asthma and allergic rhinitis (AR), based on skin prick test (SPT) and its seasonal variation

Thumbnail

D2.350 - CVID: the crossroad between immune dysregulation, autoimmunity and cancer

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Thumbnail

D2.36 - Clinical Outcomes Of Dental Procedures In Patients With Hereditary Angioedema

Thumbnail

D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Current page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM